10x Genomics (TXG) Net Cash Flow (2018 - 2026)

10x Genomics has disclosed Net Cash Flow across 9 years of filings, most recently posting $16.4 million for Q1 2026.

• Net Cash Flow for Q1 2026 came in at $16.4 million, down 50.15% year-over-year; the trailing twelve-month figure through Mar 2026 was $112.9 million (up 430.62% YoY), and the FY2025 annual result was $129.4 million, up 959.73% from the prior year.
• Net Cash Flow came in at $16.4 million for Q1 2026 at 10x Genomics, down from $41.2 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $112.4 million in Q1 2023 to a low of -$275.9 million in Q1 2022.
• The 5-year median for Net Cash Flow is $16.4 million (2026), against an average of -$6.2 million.
• Across the five-year window, Net Cash Flow plunged 903.58% in 2022 and jumped 1051.66% in 2025, its largest moves.
• 10x Genomics' Net Cash Flow stood at -$14.4 million in 2022, then jumped by 407.79% to $44.5 million in 2023, then tumbled by 221.03% to -$53.8 million in 2024, then surged by 176.57% to $41.2 million in 2025, then plunged by 60.23% to $16.4 million in 2026.
• The last three Net Cash Flow figures came in at $16.4 million (Q1 2026), $41.2 million (Q4 2025), and $35.0 million (Q3 2025), per Business Quant data.